ArticleBMC cancer2025
Two-stage augmentation for detecting malignancy of BI-RADS 3 lesions in early breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn view of inherent attributes of breast BI-RADS 3, benign and malignant lesions are with a subtle difference and the imbalanced ratio (with a very small part of malignancy). The objective of this study is to improve the detection rate of BI-RADS 3 malignant lesions on breast ultrasound (US) images using deep convolution networks.
methodsIn the study, 1,275 lesions out of 1,096 patients were included from Southwest Hospital (SW) and Tangshan Hospital (TS). In which, 629 lesions, 218 lesions and 428 lesions were utilized for the development dataset, the internal and external testing set. All malignant lesions were biopsy-confirmed, while benign lesions were verified through biopsy or stable (no significant changes) over a three-year follow-up. And each lesion had both B-mode and color Doppler images. We proposed a two-step augmentation method, covering malignancy feature augmentation and data augmentation, and further verified its feasibility on a dual-branches ResNet50 classification model named Dual-ResNet50. We conducted a comparative analysis between our model and four radiologists in breast imaging diagnosis.
resultsAfter malignancy feature and data augmentations, our model achieved a high area under the receiver operating characteristic curve (AUC) of 0.881 (95% CI: 0.830-0.921), the sensitivity of 77.8% (14/18), in the SW test set, and an AUC of 0.880 (95% CI: 0.847-0.910), a sensitivity of 71.4% (5/7) in the TS test set. Compared to four radiologists with over 10-years of diagnostic experience, our model outperformed their diagnoses.
conclusionsOur proposed augmentation method can help the deep learning (DL) classification model to improve the breast cancer detection rate in BI-RADS 3 lesions, demonstrating its potential to enhance diagnostic accuracy in early breast cancer detection. This improvement aids in a timely adjustment of subsequent treatment for these patients in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.